Linaclotide
Also known as: Linzess, Constella, Linaclotida
Molecular Identifiers
Overview
Guanylate cyclase-C (GC-C) receptor agonist peptide, composed of 14 amino acids with three disulfide bonds and a molecular weight of approximately 1,526.8 Da. Approved for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation. Acts locally in the intestine with minimal systemic absorption.
Approved by the FDA as Linzess (2012) for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC) in adults.
CCEYCCNPACTGCY Cys-Cys-Glu-Tyr-Cys-Cys-Asn-Pro-Ala-Cys-Thr-Gly-Cys-Tyr Half-life
~3-5 minutes (local, intestinal)
Administration Route
Oral
Category
Specialized Research
Mechanism of Action
- Activation of the guanylate cyclase-C (GC-C) receptor on intestinal epithelial cells
- Increased intracellular cGMP (cyclic guanosine monophosphate) production
- Stimulation of chloride and bicarbonate secretion into the intestinal lumen
- Increased intestinal fluid secretion and acceleration of transit
- Reduction of visceral pain via extracellular cGMP signaling on afferent nerves
- Inhibition of visceral afferent nociceptors
Dosage Protocol
Data compiled from the literature. This does not constitute medical advice.
| Parameter | Value |
|---|---|
| Dose | 72-290 mcg oral (subcutaneous research 100-500 mcg) |
| Frequency | Once daily (oral) |
| Timing | 30 minutes before the first meal of the day |
| Duration | Continuous use (oral) or 4-8 weeks (research) |
Reported Side Effects
Adverse effects described in the literature. Severity and frequency vary between individuals.
- Diarrhea
- Abdominal pain
- Flatulence
- Abdominal distension
Presentations & Preparation
Vials of Linaclotide found in the research market:
Reconstitution
- Diluent: Bacteriostatic water (for research formulation)
- Volume: 1-2 ml per vial
- For oral use, administer intact capsules — do not open or chew
- For subcutaneous research, reconstitute with sterile diluent
- Gently swirl until completely dissolved — never shake
Storage
- Lyophilized: Refrigerated 2-8°C (research); room temperature for commercial capsules
- Reconstituted: Refrigerated 2-8°C (up to 14 days)
- Protect from moisture (capsules)
- Keep in original packaging until use
- Do not freeze after reconstitution
Scientific Studies
Published studies on Linaclotide.
Two Randomized Trials of Linaclotide for Chronic Constipation
Lembo AJ, Schneier HA, Shiff SJ, Kurtz CB, MacDougall JE, Jia XD, et al.
Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial
Chey WD, Lembo AJ, Lavins BJ, Shiff SJ, Kurtz CB, Currie MG, et al.
Related Peptides
Aviptadil
50-150 mcg per administration (IV or subcutaneous) · 1-3 times daily per protocol
B7-33
100-500 mcg per injection (subcutaneous) · Once daily
Bronchogen
5-10 mg per day via subcutaneous injection · Once daily
Cardiogen
5-10 mg per day subcutaneously · Once daily
Chonluten
5-10 mg per day subcutaneously · Once daily
Crystagen
5-10 mg per day via subcutaneous injection · Once daily